Covalon Technologies (COV) Q3 2025 earnings summary

Executive summary

• Achieved sequential quarter-on-quarter revenue growth of 10.4% and adjusted EBITDA growth of 52% in Q3 FY2025, fulfilling prior guidance and demonstrating strong operational execution.

• Trailing twelve months revenue grew 13% to $33.0M, with adjusted EBITDA more than doubling and outpacing market growth.

• Cash on hand increased to over $18 million as of June 30, 2025, up $8.7 million year-over-year, with no debt and positive cash generation for five consecutive quarters.

• Advanced clinical evidence and market development, including peer-reviewed VALGuard studies and new product indications, supporting future growth.

• Expanded international presence with product registrations in Canada, Brazil, Panama, new distribution agreements, and tender wins in India and other regions.

Financial highlights

• Q3 FY2025 revenue was $8.4 million, up 10.4% sequentially but down 9% year-over-year; gross margin was 46.5% (down from 58.9% YoY), impacted by $830K in inventory-related charges.

• Adjusted gross margin exceeded 55% after excluding one-time inventory charges; Q3 adjusted EBITDA was just under $1 million, up over 50% sequentially.

• Year-to-date revenue grew 8% to $24.1 million, with adjusted EBITDA at $3 million, slightly down from last year.

• Operating expenses remained in the high 40s as a percent of revenue, with Q3 at $4.0 million (47.4% of revenue).

• Cash on hand at quarter-end was $18.1 million, providing flexibility for investments and capital allocation.

Outlook and guidance

• Management expects continued sequential revenue growth in Q4 and remains bullish on strong growth into next year, supported by new clinical evidence and product innovations.

• Margins are expected to stabilize following one-time Q3 events, supporting improved EBITDA in Q4 and beyond.

• The new "mud flap" use case for CovaClear IV is seen as a multimillion-dollar opportunity with a total addressable market in the tens of millions.

• Clear multi-year growth opportunity highlighted, with focus on commercial advancement, innovation, and operational optimization.